Prevention of Syncope Trial - POST
Description:
The goal of the trial is to evaluate treatment with the beta-blocker metoprolol for the prevention of vasovagal syncope.
Hypothesis:
Beta-blocker therapy with metoprolol will increase the time to the first recurrence of syncope compared with placebo.
Study Design
Patients Enrolled: 220
Mean Follow Up: 1 year
Patient Populations:
Positive tilt test with 3 syncopal spells preceding the tilt test
Exclusions:
Seizures or other causes of syncope; important heart disease; a contraindication to or need for beta blockers; a permanent pacemaker; a major noncardiovascular disease; or previous use of beta blockers at a dose greater than the equivalent of metoprolol 25mg twice daily for the purpose of suppressing vasovagal syncope.
Primary Endpoints:
Time to first syncope recurrence
Secondary Endpoints:
Syncope frequency, presyncope, and quality of life
Drug/Procedures Used:
Patients will be randomized 1:1 to receive metoprolol or placebo, and followed for 1 year.
Principal Findings:
Not yet reported
References:
Sheldon R, et al. Prevention of Syncope Trial (POST): a randomized clinical trial of beta blockers in the prevention of vasovagal syncope; rationale and study design. Europace. 2003 Jan;5(1):71-5
Keywords: Recurrence, Syncope, Vasovagal, Tilt-Table Test, Metoprolol
< Back to Listings